Search Results
10
Everything
Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update
February 27, 2025 16:10 ET
|
Merus N.V.
- Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC and petosemtamab monotherapy in 2/3L r/m HNSCC enrolling; expected to be substantially...
Merus to Present at Upcoming Investor Conferences
February 25, 2025 08:00 ET
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific...
Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma
February 18, 2025 08:00 ET
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific...
Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit
February 13, 2025 08:00 ET
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific...
New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer
February 05, 2025 17:00 ET
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative,...
Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs
January 12, 2025 20:04 ET
|
Merus N.V.
NEW HAVEN, Conn. and UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 12, 2025 (GLOBE NEWSWIRE) -- Biohaven Ltd. (NYSE: BHVN) and Merus N.V. (Nasdaq:MRUS), today announced a research...
Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC
December 16, 2024 16:01 ET
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific...
Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC
December 07, 2024 01:30 ET
|
Merus N.V.
Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing HNSCC ongoing with clinical data update planned for 2025 Petosemtamab in mCRC evaluation expanded to include 1L and 3L+;...
Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study
December 04, 2024 16:55 ET
|
Merus N.V.
BIZENGRI® is the first and only therapy approved by the FDA specifically for pancreatic adenocarcinoma and NSCLC that harbor NRG1 gene fusions and are advanced unresectable or metastatic1Merus and...
Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive
December 02, 2024 08:00 ET
|
Merus N.V.
UTRECHT, Pays-Bas et CAMBRIDGE, Massachusetts, 02 déc. 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS) (Merus, la Société, nous ou notre), une société du secteur de l’oncologie au stade...